Tenax Therapeutics (TENX) Market Performance
- Closing Price (24‑hour period ending 11:36 PM CET, Tuesday 20 Oct 2026): USD 1.63
- Price Movement: Up 11.76 %
- Volume Traded (last 24 h): USD 3.9 million
- Shares Outstanding: 57.3 million
- Market Capitalization: USD 77.9 million
- 12‑month Range:
- 52‑week High: USD 19.40 (07 Sep 2026)
- 52‑week Low: USD 1.31 (08 Oct 2026)
- Simple Moving Average (200 days): USD 10.61
- Month‑to‑Date Performance: Down 19.15 % since the end of September.
Comparative Performance of Related Stocks (last 24 hours)
| Symbol | Company | Price | % Change | Market Cap (USD mn) |
|---|---|---|---|---|
| LAKE | Lakeland Industries | USD 9.50 | +3.19 % | 91.6 |
| ATRA | Atara Biotherapeutics | USD 9.16 | –2.40 % | 92.2 |
| KEQU | Kewaunee Scientific Cp | USD 32.92 | –2.52 % | 93.4 |
| AIRS | Airsculpt | USD 1.30 | –2.35 % | 91.9 |
| ANIX | Anixa Biosciences | USD 2.68 | –2.25 % | 92.8 |
Corporate Actions – Atara Biotherapeutics
Atara Biotherapeutics (ATRA) announced the appointment of former chief financial officer Utpal Koppikar to its board of directors. Mr. Koppikar previously held senior finance positions at Gilead Sciences, Amgen, and Atara, and served as CFO at Verily Health. The company emphasized that his experience supports its growth strategy and pipeline development. No additional guidance or financial disclosures were issued.
Company Overview – Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialty pharmaceutical company operating in the Health Care sector with a focus on Biotechnology. Headquartered in Morrisville, United States, the company develops and commercializes products for the critical care market, targeting pulmonary hypertension associated with heart failure and preserved ejection fraction (PH‑HFPf). Tenax utilizes levosimendan as an active ingredient in its product development. Further information can be obtained from the company’s website at www.tenaxthera.com and through its NASDAQ listing.
